linical Trial |
NCT Number |
Sponsor |
Condition |
Start Date |
Phase |
NCT05931367 |
Eli Lilly and Company |
Obesity|Overweight|Osteo Arthritis Knee
|
August 28, 2023 |
Phase 3 |
NCT05929066 |
Eli Lilly and Company |
Obesity|Overweight|Knee Pain Chronic|Knee Osteoarthritis|Obstructive Sleep Apnea
|
August 7, 2023 |
Phase 3 |
NCT05882045 |
Eli Lilly and Company |
Obesity|Cardiovascular Diseases
|
May 30, 2023 |
Phase 3 |
NCT05611957 |
Eli Lilly and Company |
Healthy|Renal Insufficiency
|
November 16, 2022 |
Phase 1 |
NCT04881760 |
Eli Lilly and Company |
Obesity|Overweight
|
May 20, 2021 |
Phase 2 |
NCT05445232 |
Eli Lilly and Company |
Obesity
|
July 8, 2022 |
Phase 1 |
NCT04823208 |
Eli Lilly and Company |
Diabetes Mellitus, Type 2
|
May 24, 2021 |
Phase 1 |
NCT05936151 |
Eli Lilly and Company |
Overweight or Obesity|CKD|Type 2 Diabetes
|
July 20, 2023 |
Phase 2 |
NCT06003465 |
Eli Lilly and Company |
Healthy
|
August 29, 2023 |
Phase 1 |
NCT05916560 |
Eli Lilly and Company |
Healthy|Hepatic Insufficiency
|
July 13, 2023 |
Phase 1 |
NCT05929079 |
Eli Lilly and Company |
Type 2 Diabetes|Obesity|Overweight|Obstructive Sleep Apnea
|
July 11, 2023 |
Phase 3 |
NCT05548231 |
Eli Lilly and Company |
Overweight|Obesity
|
October 24, 2022 |
Phase 1 |
NCT04143802 |
Eli Lilly and Company |
Diabetes Mellitus, Type 2
|
December 18, 2019 |
Phase 1 |
NCT05959096 |
Eli Lilly and Company |
Healthy
|
July 18, 2023 |
Phase 1 |
NCT03841630 |
Eli Lilly and Company |
Healthy
|
March 13, 2019 |
Phase 1 |
NCT04867785 |
Eli Lilly and Company |
Type 2 Diabetes
|
May 13, 2021 |
Phase 2 |
|